Weight-Loss Jabs Show Promise in Easing Symptoms of Deadly Heart Failure

Researchers have made a breakthrough discovery regarding the effects of weight-loss jabs on heart failure, a condition that affects around half a million people in Britain and is growing in Ireland. A trial found that semaglutide, a medication commonly known under the brand names Ozempic and Wegovy, helped patients lose weight and improve their symptoms, including shortness of breath, fatigue, and swelling in the legs and feet. The study, involving 1,145 patients, analyzed the effects of a weekly 2.4mg jab over the course of a year, revealing that women shed more weight, losing an average of 9.6% of their body weight compared to 7.2% in men.

Key Takeaways:

• The study found that semaglutide helped patients with preserved ejection fraction (HFpEF) heart failure, a condition where the heart pumps normally but is too stiff to fill properly, lose weight and improve their symptoms, regardless of sex.
• Women shed more weight on average, losing 9.6% of their body weight compared to 7.2% in men.
• The jabs improved heart-failure symptoms, such as shortness of breath, fatigue, and swelling in the legs and feet, in both sexes.
• Patients were able to do more exercise and had reduced levels of inflammation.
• The study involved 1,145 patients, aged between 50 and 75, with a history of HFpEF.
• The trial lasted for a year, with patients receiving a weekly 2.4mg jab of semaglutide.
• Dr. John S. Floras, a co-author of the study, noted that the findings suggest that semaglutide may also be addressing an underlying mechanism of heart failure.
• The study's results were presented in the Journal of the American College of Cardiology, and were hailed as one of the most significant developments in heart disease since the introduction of statins.

Statistics:

• 1,145 patients participated in the study.
• Patients lost an average of 9.6% of their body weight (women) and 7.2% (men) over the course of the year.
• Patients experienced improved heart-failure symptoms, including shortness of breath, fatigue, and swelling in the legs and feet.
• Patients were able to do more exercise, with a corresponding decrease in inflammation.
• The study was the first to analyze the effects of semaglutide on men and women separately in relation to HFpEF.

Sources:

• The New York Times, (no date)
• European Congress of Obesity (2023)
• Journal of the American College of Cardiology (2023)